Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2021	Sep. 30, 2021
CURRENT ASSETS
Cash and cash equivalents	$ 91,587	$ 184,434
Accounts receivable	150	10,255
Prepaid expenses	5,199	4,362
Other current assets	2,795	2,191
Marketable securities	126,010	126,728
Short term investments	112,537	56,627
TOTAL CURRENT ASSETS	338,278	384,597
Property and equipment, net	52,303	48,675
Intangible assets, net	13,238	13,663
Long term investments	217,572	245,595
Right-of-use assets	16,875	17,346
Other assets	273	272
TOTAL ASSETS	638,539	710,148
CURRENT LIABILITIES
Accounts payable	4,068	9,457
Accrued expenses	18,518	14,001
Accrued payroll and benefits	2,968	9,773
Lease liabilities	2,826	2,250
Deferred revenue	108,652	111,055
TOTAL CURRENT LIABILITIES	137,032	146,536
LONG-TERM LIABILITIES
Lease liabilities, net of current portion	22,489	23,295
Deferred revenue, net of current portion	106,458	131,495
TOTAL LONG-TERM LIABILITIES	128,947	154,790
Commitments and contingencies (Note 7)
Arrowhead Pharmaceuticals, Inc. stockholders’ equity:
Common stock, $0.001 par value; 145,000 shares authorized; 104,798 and 104,327 shares issued and outstanding as of December 31, 2021 and September 30, 2021, respectively	197	197
Additional paid-in capital	1,080,035	1,053,386
Accumulated other comprehensive income	(108)	(69)
Accumulated deficit	(707,564)	(644,692)
TOTAL STOCKHOLDERS’ EQUITY	372,560	408,822
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 638,539	$ 710,148